Biogen Acquires Ionis’ Spinal Muscular Atrophy Candidate As Spinraza Loses Its Shine

Pays $60m Upfront

 
• By Ayisha Sharma

The firm has stumped up $60m for Ionis’s preclinical antisense asset in spinal muscular atrophy, a potential successor to the slowing Spinraza, which also faces patent expiry in a few years.

Box of Spinraza in the foreground, young child in the background
BIIB115 Is Set To Replace Spinraza, Which Could Be Left On The Shelf • Source: Alamy

More from Deals

More from Business